ClinicalTrials.gg

von Hippel-Lindau Disease clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 55 studies for von Hippel-Lindau Disease across more than 10 countries. 23 are recruiting or about to start. 36 of them are mainly about von Hippel-Lindau Disease (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13.

Status

Recruiting
20
Completed
19
Terminated
7
Active, not recruiting
4
Not yet recruiting
2
Enrolling by invitation
1

Phase

Phase 2
18
Phase 1
9
Early Phase 1
2
Phase 3
1

Where

United States
33
China
8
France
7
Italy
6
Denmark
5
Japan
3

Who develops what

Add von Hippel-Lindau Disease to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 1 program from 1 company, 1 with this as their studies’ main aim; 1 with a live phase 3 study; 1 primary completion in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
NivolumabRecent, limited
Evidence
  • NCT07405164 · Merck & Co., Inc · Phase 3 · live · background · “Nivolumab” · registered Feb 2026
Bristol-Myers Squibb76% of its industry studiesUS: Bristol-Myers Squibb (FDA 2014)EU: Bristol-Myers Squibb (EMA 2015)11 study
lenvatinibRecent, limited
Evidence
  • NCT07405164 · Merck & Co., Inc · Phase 3 · live · background · “Lenvatinib” · registered Feb 2026
Eisai Co., Ltd.63% of its industry studiesUS: Eisai Co., Ltd. (FDA 2015)EU: Eisai Co., Ltd. (EMA 2015)11 study

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 1 program — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 29 Apr 2027 est.belzutifan · Merck & Co., Inc · Phase 2 main aimNCT03401788 A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004) — primary endpoint: Objective Response Rate (ORR) in VHL Disease-Associated RCC Tumors · 50 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in von Hippel-Lindau Disease studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 1 open · Angiogenesis inhibitors 6

Coming up

6studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 6

Who these studies take

Of the 20 von Hippel-Lindau Disease studies recruiting now, 16 (80%) set no upper age limit and 0 (0%) stop at 75 or younger. 9 (45%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 5 (25%) take healthy volunteers.

Recruiting studies that take each age, of 20
AgeWomenMen
105 (25%)5 (25%)
1820 (100%)20 (100%)
3020 (100%)20 (100%)
4020 (100%)20 (100%)
5020 (100%)20 (100%)
6520 (100%)20 (100%)
7520 (100%)20 (100%)
8517 (85%)17 (85%)

Across all 55 studies, recruiting or not: 5% stop at 75 or younger and 4% at 65; 36% take children; 0% are for women only and 0% for men only; 9% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

What changed recently

From the registry's own updates since Oct 19, 2026.

Started recruiting1

Studies

Recruiting first, then most recently updated. Showing 50 of 55. Browse all 55 → or search them.